Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...
Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents ...
Social determinants of health influence heart failure and arrhythmia risk in HCM, highlighting the need for more holistic, ...
The Great Blue Hole in Belize is a massive ... hole that’s roughly 300m in diameter and over 120m deep, said to be formed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback